Skip to main content
SpringerLink
Log in

Clinical considerations are paramount when prescribing metoprolol

  • New Drugs and Therapeutics
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Yedinak KC. Formulary considerations in selection of β-blockers. PharmacoEconomics 1993; 4: 104–21

    Article  PubMed  CAS  Google Scholar 

  2. Peters DH, Benfield P. Metoprolol. A pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy. PharmacoEconomics 1994; 6: 370–400

    Article  PubMed  CAS  Google Scholar 

  3. Wikstrand J, Warnold I, Olsson G, et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988; 259: 1976–82

    Article  PubMed  CAS  Google Scholar 

  4. Olsson G, Rehnqvist N, Sjögren A, et al. Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol 1985; 5: 1428–37

    Article  PubMed  CAS  Google Scholar 

  5. Johannesson M, Wikstrand J, Jönsson B, et al. Cost-effectiveness of antihypertensive treatment. Metoprolol versus thiazide diuretics. PharmacoEconomics 1993; 3: 36–44

    Article  PubMed  CAS  Google Scholar 

  6. Olsson G, Levin L-Å, Rehnqvist N. Economic consequences of postinfarction prophylaxis with β blockers: cost effectiveness of metoprolol. BMJ 1987; 294: 339–42

    Article  PubMed  CAS  Google Scholar 

  7. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5

    Article  PubMed  Google Scholar 

  8. Johanneson M, Dahlöf B, Lindholm LH, et al. The cost-effectiveness of treating hypertension in elderly people — an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J Intern Med 1993; 234: 317–23

    Article  Google Scholar 

  9. Eagle KA, Blank DJ, Aguiar E, et al. Economic impact of regression of left ventricular hypertrophy by antihypertensive drugs. J Hum Hypertension 1993; 7: 341–51

    CAS  Google Scholar 

  10. Dahlöf C, Almkvist G, Dimenäs E, et al. No difference in well-being during antihypertensive treatment with atenolol or metoprolol CR. Ann Clin Res 1988; 20 Suppl. 48: 42–50

    PubMed  Google Scholar 

  11. Dimenäs E, Östergren J, Lindvall K, et al. Comparisons of CNS-related subjective (CR/ZOK) formulation of metoprolol or atenolol. J Clin Pharmacol 1990; 30: S82–90

    PubMed  Google Scholar 

  12. Dahlöf C, Hedner T, Thulin T, et al. Effects of diltiazem and metoprolol on blood pressure, adverse symptoms and general well-being. Eur J Clin Pharmacol 1991; 40: 453–60

    Article  PubMed  Google Scholar 

  13. Frimodt-Moeller J, Lodrup Poulsen D, Kornerup HJ, et al. Quality of life, side effects and efficacy of lisinopril compared with metoprolol in patients with mild to moderate essential hypertension. J Hum Hypertens 1991; 5: 215–21

    PubMed  CAS  Google Scholar 

  14. Omvik P, Leer J, Istad H, et al. Equal efficacy and improved tolerability with 50mg controlled-release metoprolol compared with 100mg conventional metoprolol in hypertensive patients. Am J Ther 1994; 1: 65–73

    Article  PubMed  Google Scholar 

  15. O’Brien BJ, Buxton MJ, Patterson DL. Relationship between functional status and health-related quality-of-life after myocardial infarction. Med Care 1993; 31: 950–5

    Article  PubMed  Google Scholar 

  16. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in diopathic dilated cardiomyopathy. Lancet 1993; 342: 1441–6

    Article  PubMed  CAS  Google Scholar 

  17. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153: 154–83

    Article  Google Scholar 

  18. Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993; 306: 983–7

    Article  PubMed  CAS  Google Scholar 

  19. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker Oxprenolol: the international prospective primary prevention study in hypertension (IPPPSH). J Hypertension 1985; 3: 379–92

    Article  Google Scholar 

  20. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97–104

    Article  Google Scholar 

  21. Wilhemsen L, Berglund G, Elmfeldt D, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertension 1987; 5: 561–72

    Article  Google Scholar 

  22. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12

    Article  Google Scholar 

  23. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852–7

    Article  PubMed  CAS  Google Scholar 

  24. 1994 Physicians Genrx. New York: Data Pharmaceutica Inc., 1994: II–1508–11

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clinical considerations are paramount when prescribing metoprolol. Drugs Ther. Perspect 5, 1–5 (1995). https://doi.org/10.2165/00042310-199505060-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199505060-00001

Keywords

Search

Navigation